Acuitive Technologies, Inc. Appoints Dr. Wayne Berberian As Chief Medical Officer
ALLENDALE, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Acuitive Technologies (Acuitive), a leading orthopedic medical device company focused on complex soft tissue repair and regeneration, announces the appointment of Wayne Berberian, M.D. as Chief Medical Officer. He will provide the clinical direction for the development of regenerative orthopedic products from the company's portfolio of innovative biomaterials.
With over 30 years of experience in senior clinical, educational, and medical executive roles for leading institutions, such as Rutgers Univ. Hospital, Rutgers Univ., New Jersey Medical School, and Hackensack Univ. Medical Center, he has a proven record of making impactful medical decisions. As a full Professor at the Hackensack Meridian School of Medicine, he uses cutting-edge orthopedic technologies to drive innovation and deliver outstanding patient care.
In addition to his prolific professional accomplishments and numerous medical accolades, Dr. Berberian has authored more than 100 peer-reviewed publications and abstracts, books, monographs, chapters, grants, and reports, and has presented over 150 lectures on“state of the art” topics. His experience and expertise will help lead Acuitive to the forefront of regenerative orthopedics that will touch millions of lives.
"I am thrilled to join Acuitive Technologies at such a transformative time," said Wayne Berberian. "I'm impressed by their unique ability to deliver patient-centric tissue regenerative solutions and mitigate the complications of current biodegradable materials. I look forward to joining their clinical decision team and making personalized treatment recommendations possible for multiple degenerative diseases for the first time. This technology has a significant transformational impact on orthopedic healthcare – repairing and regenerating musculoskeletal diseases, maximizing patient outcomes, and reducing the inefficiencies that arise from ineffective devices that can lead to secondary complications and additional surgery."
"We're delighted to welcome Dr. Berberian to the Acuitive team at a pivotal time for the company" said Mike McCarthy, CEO of Acuitive. "Our capabilities along with multiple healthcare partners are enabling us to build pioneering products that solve clinical problems and enhance patient care and outcomes. Dr. Berberian's extensive experience as a clinician and educator along with his deep understanding of healthcare innovations makes him the perfect fit to help drive the growth of our product portfolio."
About Acuitive
Acuitive is a biotechnology company developing innovative regenerative biomaterials for orthopedic devices that participate in the natural healing process of musculoskeletal tissues. Together with its surgeon customers, Acuitive is driven to improve patient outcomes by delivering best in class tissue regenerative solutions. More information is available at .
Media Contact
Thomas McCarthy
Acuitive Technologies, Inc.
...
201.661.2680
A photo accompanying this announcement is available at
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Manuka Honey Market Report 2024, Industry Growth, Size, Share, Top Compan...
- Modular Kitchen Market 2024, Industry Growth, Share, Size, Key Players An...
- Acrylamide Production Cost Analysis Report: A Comprehensive Assessment Of...
- Fish Sauce Market 2024, Industry Trends, Growth, Demand And Analysis Repo...
- Australia Foreign Exchange Market Size, Growth, Industry Demand And Forec...
- Cold Pressed Oil Market Trends 2024, Leading Companies Share, Size And Fo...
- Pasta Sauce Market 2024, Industry Growth, Share, Size, Key Players Analys...
Comments
No comment